Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBT Avalon GloboCare	$2.16 +11.3%	$2.87	$1.87 ▼ $12.60	$4.09M	-0.02	1.98 million shs	270,302 shs
EDSA Edesa Biotech	$2.14 -4.9%	$2.10	$1.55 ▼ $5.25	$15.04M	0.27	36,024 shs	18,701 shs
HOTH Hoth Therapeutics	$1.31 -1.9%	$1.24	$0.58 ▼ $3.80	$17.24M	0.66	419,612 shs	131,683 shs
MBRX Moleculin Biotech	$0.67 +5.9%	$0.61	$0.25 ▼ $3.65	$20.09M	1.39	10.38 million shs	2.13 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBT Avalon GloboCare	0.00%	-4.85%	-20.73%	-43.90%	-51.98%
EDSA Edesa Biotech	0.00%	-10.46%	+0.47%	-9.51%	-59.62%
HOTH Hoth Therapeutics	0.00%	+1.95%	+8.30%	+46.68%	+89.90%
MBRX Moleculin Biotech	0.00%	+17.30%	+90.03%	-35.43%	-78.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBT Avalon GloboCare	1.2196 of 5 stars	0.0	2.0	4.3	2.5	1.7	0.0
EDSA Edesa Biotech	1.7291 of 5 stars	2.0	5.0	0.0	0.0	1.7	0.6
HOTH Hoth Therapeutics	2.8602 of 5 stars	3.6	5.0	0.0	2.4	0.0	0.6
MBRX Moleculin Biotech	2.684 of 5 stars	3.5	2.0	0.0	2.2	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBT Avalon GloboCare	0.00	N/A	N/A	N/A
EDSA Edesa Biotech	4.00	Strong Buy	$5.00	133.64% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	206.51% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	501.41% Upside

Current Analyst Ratings Breakdown

Latest ALBT, MBRX, HOTH, and EDSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/27/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBT Avalon GloboCare	$1.33M	3.07	N/A	N/A	($11.37) per share	-0.19
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.61 per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBT Avalon GloboCare	-$7.90M	-$19.96	N/A	∞	N/A	-647.29%	N/A	-50.13%	8/18/2025 (Estimated)
EDSA Edesa Biotech	-$6.17M	-$1.59	N/A	N/A	N/A	N/A	-187.01%	-78.72%	8/8/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/4/2025 (Estimated)

Latest ALBT, MBRX, HOTH, and EDSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.42	N/A	N/A	N/A	N/A	N/A
8/8/2025	N/A	EDSA Edesa Biotech	-$0.23	N/A	N/A	N/A	N/A	N/A
8/8/2025	N/A	HOTH Hoth Therapeutics	-$0.27	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q2 2025	EDSA Edesa Biotech	-$0.30	-$0.30	N/A	-$0.30	N/A	N/A
5/13/2025	Q1 2025	ALBT Avalon GloboCare	N/A	-$1.43	N/A	-$1.43	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBT Avalon GloboCare	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBT Avalon GloboCare	N/A	0.19	0.19
EDSA Edesa Biotech	N/A	15.72	15.72
HOTH Hoth Therapeutics	N/A	15.09	15.08
MBRX Moleculin Biotech	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBT Avalon GloboCare	1.42%
EDSA Edesa Biotech	5.50%
HOTH Hoth Therapeutics	7.08%
MBRX Moleculin Biotech	15.52%

Insider Ownership

Company	Insider Ownership
ALBT Avalon GloboCare	37.30%
EDSA Edesa Biotech	22.60%
HOTH Hoth Therapeutics	6.92%
MBRX Moleculin Biotech	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBT Avalon GloboCare	5	1.89 million	1.19 million	Not Optionable
EDSA Edesa Biotech	20	7.03 million	5.44 million	Not Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
MBRX Moleculin Biotech	20	30.21 million	29.57 million	Not Optionable

ALBT, MBRX, HOTH, and EDSA Headlines

Recent News About These Companies

Moleculin Biotech Releases Corporate Presentation Update

August 1 at 5:30 PM | tipranks.com

Moleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

July 31 at 4:43 AM | finanznachrichten.de

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

July 30, 2025 | globenewswire.com

Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025 | finance.yahoo.com

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

July 17, 2025 | globenewswire.com

Moleculin Biotech enters $6.5 million at-the-market equity offering ...

July 13, 2025 | investing.com

Moleculin Biotech Enters New Stock Offering Agreement

July 11, 2025 | tipranks.com

Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 ... - Nasdaq

July 11, 2025 | nasdaq.com

Moleculin Biotech, Inc.: Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

July 9, 2025 | finanznachrichten.de

Moleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin

July 9, 2025 | msn.com

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

July 9, 2025 | globenewswire.com

Several Insiders Invested In Moleculin Biotech Flagging Positive News

July 4, 2025 | finance.yahoo.com

Moleculin Biotech Faces Nasdaq Delisting Warning

June 27, 2025 | tipranks.com

MBRX Moleculin Biotech, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Moleculin Biotech, Inc. (NASDAQ:MBRX) CFO Acquires $99,999.90 in Stock

June 24, 2025 | insidertrades.com

Moleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AML

June 20, 2025 | nasdaq.com

Moleculin Biotech prices $5.9M public offering; shares down about 47%

June 20, 2025 | msn.com

Moleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E Warrants

June 20, 2025 | quiverquant.comQ

Moleculin Announces $5.9 Million Public Offering

June 20, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT, MBRX, HOTH, and EDSA Company Descriptions

Avalon GloboCare NASDAQ:ALBT

$2.16 +0.22 (+11.34%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.12 -0.04 (-1.85%)

As of 08/1/2025 07:58 PM Eastern

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Edesa Biotech NASDAQ:EDSA

$2.14 -0.11 (-4.89%)

Closing price 08/1/2025 03:55 PM Eastern

Extended Trading

$2.25 +0.11 (+5.33%)

As of 08/1/2025 04:19 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Hoth Therapeutics NASDAQ:HOTH

$1.30 -0.03 (-1.88%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.27 -0.03 (-2.30%)

As of 08/1/2025 07:40 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Moleculin Biotech NASDAQ:MBRX

$0.67 +0.04 (+5.91%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.62%)

As of 08/1/2025 07:49 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time